Search Results
Jun 18, 2026, 06:55 ET IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization
therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations,
More news about: IASO Bio
Jun 17, 2026, 06:00 ET S&P Global Ratings Affirms Ecopetrol's Global and Stand-Alone Credit Ratings
"Company") informs that S&P Global Ratings ("S&P") has affirmed the Company's global credit rating at BB- with a stable outlook, as well as Ecopetrol's Stand-Alone Credit Profile ("SACP") at bb+. The credit rating reflects S&P's assessment as of the date hereof and is subject to change at any time.
More news about: Ecopetrol S.A.
Jun 16, 2026, 08:08 ET Global Jet Capital Completes Securitization, Raising $659.0M
tranche, and a $40.68 million Class C tranche. S&P Global Ratings and Kroll Bond Rating Agency LLC assigned BJETS 2026-1 ratings of A/A, BBB+/BBB and BB/BB on the Class A, B and C tranches, respectively. The transaction attracted 41 unique investors, 12 of which were new to the BJETS program.As with
More news about: Global Jet Capital
Jun 16, 2026, 08:00 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
anti-CD28 bead expansion protocol, which has become the global manufacturing standard for CAR-T cells. He also engineered CAR constructs incorporating the 4-1BB (CD137) co-stimulatory domain and the T-cell receptor-zeta chain (TCR-ζ) to enhance the proliferation and long-term survival of transferred T cells,
More news about: The Tang Prize Foundation
Jun 12, 2026, 09:22 ET IFS Named a Customers' Choice in the Gartner® Voice of the Customer for Cloud ERP for Product-Centric Enterprises for the Fourth Consecutive Year
https://mb.cision.com/Public/855/4362292/ac20e062bb250094_org.pngFigure 1 Voice of
More news about: IFS
Jun 10, 2026, 00:06 ET Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
vivo stability, and reduced systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, indicating an encouraging therapeutic window."Following the recent FDA IND clearance
More news about: Harbour BioMed
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jun 09, 2026, 13:44 ET CRRC Zhuzhou Institute apresentará sistema de armazenamento de energiarefrigerado a líquido 6.X na The smarter E Europe 2026
https://mma.prnewswire.com/media/2996053/8eb3b12d7299010647058ecae5d76bb0.mp4Foto - https://mma.prnewswire.com/media/2996054/2026Intersolar.jpg
More news about: CRRC Zhuzhou Institute
Jun 09, 2026, 13:35 ET El CRRC Zhuzhou Institute presentará elsistema de almacenamiento de energía refrigerado por líquido 6.X en The Smarter E Europe 2026
https://mma.prnewswire.com/media/2996055/8eb3b12d7299010647058ecae5d76bb0.mp4Foto - https://mma.prnewswire.com/media/2996056/2026Intersolar.jpg
More news about: CRRC Zhuzhou Institute
Jun 09, 2026, 12:11 ET CRRC Zhuzhou Institute présentera le système de stockage d'énergie à refroidissement liquide 6.X au salon Smarter E Europe 2026
https://mma.prnewswire.com/media/2995967/8eb3b12d7299010647058ecae5d76bb0.mp4Photo - https://mma.prnewswire.com/media/2995969/2026Intersolar.jpg
More news about: CRRC Zhuzhou Institute
Jun 08, 2026, 18:47 ET CRRC Zhuzhou Institute presentará el sistema de almacenamiento de energía refrigerado por líquido 6.X
https://mma.prnewswire.com/media/2995967/8eb3b12d7299010647058ecae5d76bb0.mp4Foto - https://mma.prnewswire.com/media/2995969/2026Intersolar.jpg
More news about: CRRC Zhuzhou Institute
Jun 08, 2026, 18:39 ET Das CRRC Zhuzhou Institute präsentiert auf der „The Smarter E Europe 2026" das flüssigkeitsgekühlte Energiespeichersystem 6.X
https://mma.prnewswire.com/media/2995967/8eb3b12d7299010647058ecae5d76bb0.mp4Foto - https://mma.prnewswire.com/media/2995969/2026Intersolar.jpg
More news about: CRRC Zhuzhou Institute
-RBC_Global_Asset_Management_E.jpg?id=OA2689075&w=300)
Jun 08, 2026, 11:00 ET RBC Global Asset Management Expands Alternative Product Set with Launch of New Interval Fund
CLOs, with the flexibility to invest in other structured credit securities. CLO tranches are bond securities backed by a pool of corporate loans with BB and B credit ratings. Regionally, the Fund will focus predominantly on the U.S. market but may also allocate investments to European CLOs. Equity and
More news about: RBC Global Asset Management (U.S.)
Jun 08, 2026, 10:34 ET CRRC Zhuzhou Institute to Showcase 6.X Liquid-Cooled Energy Storage System at The Smarter E Europe 2026
https://mma.prnewswire.com/media/2995967/8eb3b12d7299010647058ecae5d76bb0.mp4Photo - https://mma.prnewswire.com/media/2995969/2026Intersolar.jpg
More news about: CRRC Zhuzhou Institute
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jun 05, 2026, 17:01 ET Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research
https://www.alliedmarketresearch.com/checkout-final/63f8fee53b6b6e916559861689c43bb3Segment AnalysisBy Type: Pathogen Leads, GMO and Chemical Testing
More news about: Allied Market Research
Jun 03, 2026, 07:30 ET V2X to Generate Interest Expense Savings Through Successful Term Loan Repricing
margin of 2.0%, with an additional 25 basis-point-reduction upon achieving specific corporate credit ratings of Ba3 (stable outlook) from Moody's and BB (stable outlook) from S&P. The repricing also reduced the SOFR floor from 0.75% to 0.00%.
More news about: V2X, Inc.
Jun 03, 2026, 00:00 ET Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jun 02, 2026, 10:00 ET Splitero Closes $296 Million Home Equity Investment Securitization
A-1 rated A (low) (sf), $56.8 million of mezzanine class A-2 securities rated BBB (low) (sf), $15.6 million of subordinate class B-1 securities rated BB (sf), and $20.77 million of subordinate class B-2 securities rated B (sf), all rated by Morningstar DBRS. The deal received outstanding market
More news about: Splitero
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
May 27, 2026, 17:30 ET Primis Financial Corp. Announces Election of New Board Members Scott Gamble and Brock Saunders
Partners, L.P. and has more than 38 years of banking experience. Prior to joining Patriot, Mr. Gamble served as Regional President for BB&T's Greater Delaware Valley Region, where he oversaw commercial and retail management teams as well as commercial real estate and regional corporate
More news about: Primis Financial Corp.
May 27, 2026, 07:00 ET Warner Bros. Discovery Announces Receipt of Requisite Consents for Proposed Amendments in Consent Solicitations
USU55632AT7555903V BB8 US55903VBB8055903V AJ2
More news about: Warner Bros. Discovery, Inc.
May 26, 2026, 00:00 ET SK chemicals' sieben Kunststoffmaterialien als kompatibel mit europäischen Recyclingprozessen bestätigt
Maßstab dafür, ob der Behälter im tatsächlichen Recyclingprozess problemlos verarbeitet werden kann. Die Flasche bestand aus den Materialien SKYPET CR BB und SKYPET CR BL.
More news about: SK chemicals
May 26, 2026, 00:00 ET SK chemicals' Seven Plastic Materials Confirmed Compatible with European Recycling Processes
serves as a benchmark for determining whether the container can be processed without issues during actual recycling. The bottle incorporated SKYPET CR BB and SKYPET CR BL.
More news about: SK chemicals